Peginterferon add-on results in more HBsAg decline compared to monotherapy in HBeAg-positive chronic hepatitis B patients

Journal of Viral Hepatitis

Volumn 23, Issue 6, 2016, Pages 419-426

  Brouwer, W P ^a   Sonneveld, M J ^a   Xie, Q ^b   Guo, S ^b   Zhang, N ^c   Zeuzem, S ^d   Tabak, F ^e   Zhang, Q ^c   Simon, K ^f   Akarca, U S ^g   Streinu Cercel, A ^h   Hansen, B E ^a   Janssen, Harry L A ^a,i  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^e ISTANBUL UNIVERSITY   (Turkey)

^f WROCLAW MEDICAL UNIVERSITY   (Poland)

^g EGE UNIVERSITY   (Turkey)

^h Clinical Institute Fundeni   (Romania)

ⁱ TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

combination therapy; ETV consolidation; PEG IFN add on; viral hepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON; ALPHA INTERFERON; ANTIVIRUS AGENT; GUANINE;

ADD ON THERAPY; ADULT; ARTICLE; CHRONIC HEPATITIS B; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; ANALOGS AND DERIVATIVES; BLOOD; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; HEPATITIS B, CHRONIC; MIDDLE AGED; PROCEDURES; RETROSPECTIVE STUDY; SEROCONVERSION; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SEROCONVERSION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84945555058     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12468     Document Type: Article

References (29)

1. Chang TT, Lai CL, Kew Yoon S, et al,. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51 (2): 422-430.
2. Chang TT, Liaw YF, Wu SS, et al,. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52 (3): 886-893.
3. Zoutendijk R, Reijnders JG, Zoulim F, et al,. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut 2013; 62 (5): 760-765.
4. Marcellin P, Gane E, Buti M, et al,. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381 (9865): 468-475.
5. Moucari R, Korevaar A, Lada O, et al,. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol 2009; 50 (6): 1084-1092.
6. Niederau C, Heintges T, Lange S, et al,. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334 (22): 1422-1427.
7. van Zonneveld M, Honkoop P, Hansen BE, et al,. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004; 39 (3): 804-810.
8. Lin SM, Yu ML, Lee CM, et al,. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007; 46 (1): 45-52.
9. Chan HL, Wong VW, Tse AM, et al,. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007; 5 (12): 1462-1468.
10. Wursthorn K, Lutgehetmann M, Dandri M, et al,. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44 (3): 675-684.
11. Sonneveld MJ, Hansen BE, Piratvisuth T, et al,. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology 2013; 58 (3): 872-880.
12. Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL,. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010; 52 (4): 1251-1257.
13. Sonneveld MJ, Rijckborst V, Cakaloglu Y, et al,. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-alpha2b: relation to response and HBV genotype. Antivir Ther 2012; 17 (1): 9-17.
14. Boni C, Laccabue D, Lampertico P, et al,. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology 2012; 143 (4): 963-73.e9.
15. Tjwa ET, van Oord GW, Hegmans JP, Janssen HL, Woltman AM,. Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B. J Hepatol 2011; 54 (2): 209-218.
16. Chan HL, Leung NW, Hui AY, et al,. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005; 142 (4): 240-250.
17. Janssen HL, van Zonneveld M, Senturk H, et al,. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365 (9454): 123-129.
18. Lau GK, Piratvisuth T, Luo KX, et al,. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352 (26): 2682-2695.
19. Marcellin P, Lau GK, Bonino F, et al,. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351 (12): 1206-1217.
20. Marcellin P, Ahn SH, Ma X, et al,. HBsAg loss with tenofovir disoproxil fumarate (TDF) plus Peginterferon alfa-2a (PEG) in Chronic hepatitis B (CHB): results of a global randomized controlled trial. Hepatology 2014; abstract 193(Suppl. S1): 294A-299A.
21. Brouwer WP, Xie Q, Sonneveld MJ, et al,. Adding peginterferon to entecavir for HBeAg-positive chronic hepatitis B: a multicentre randomized trial (ARES study). Hepatology 2014; 61: 1512-1522. doi: 10.1002/hep.27586.
22. Chan HL, Wong VW, Wong GL, Tse CH, Chan HY, Sung JJ,. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 2010; 52 (4): 1232-1241.
23. Wursthorn K, Jung M, Riva A, et al,. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 2010; 52 (5): 1611-1620.
24. Robins JM, Hernan MA, Brumback B,. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11 (5): 550-560.
25. Buster EH, Hansen BE, Lau GK, et al,. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009; 137 (6): 2002-2009.
26. Chan HL, Wong VW, Chim AM, et al,. Virological response to different combination regimes of peginterferon alpha-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B. Antivir Ther 2007; 12 (5): 815-823.
27. Xie Q, Zhou H, Bai X, et al,. A randomized, open-label clinical study of combined pegylated interferon alfa-2a (40KD) and entecavir treatment for hepatitis B "e" antigen-positive chronic hepatitis B. Clin Infect Dis 2014; 59: 1714-1723.
28. Zoulim F, Carosi G, Greenbloom S, et al,. Quantification of HBsAg in nucleos(t)ide-naive patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study. J Hepatol 2014; 62: 56-63.
29. Chen CH, Lu SN, Hung CH, et al,. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment. J Hepatol 2014; 61 (3): 515-522.